Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
symbols : PSTX save search
Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting
Published: 2024-04-18 (Crawled : 19:00) - biospace.com/
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: 0.25%
H: 0.0%
C: 0.0%
cell meeting therapeutics therapy
Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus
Published: 2024-04-17 (Crawled : 15:00) - biospace.com/
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: 0.0%
H: 2.46%
C: 0.49%
day pipeline therapeutics therapy
Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma
Published: 2024-04-08 (Crawled : 00:00) - biospace.com/
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -0.67%
H: 0.0%
C: 0.0%
car-t therapeutics potential therapy
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-01 (Crawled : 20:00) - prnewswire.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -1.79%
H: 1.0%
C: -3.65%
nasdaq grant therapeutics
Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer
Published: 2024-03-25 (Crawled : 20:00) - prnewswire.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: 1.64%
H: 0.97%
C: -9.06%
medical therapeutics
Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
Published: 2024-03-19 (Crawled : 20:00) - prnewswire.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -1.03%
H: 6.94%
C: 3.13%
conference cell therapeutics therapy
Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma
Published: 2024-03-13 (Crawled : 20:00) - prnewswire.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -0.88%
H: 0.0%
C: -4.14%
fda drug granted treatment designation therapeutics
Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023
Published: 2024-03-07 (Crawled : 23:00) - biospace.com/
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: 0.84%
H: 0.28%
C: -5.25%
year therapeutics financial results
Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-04 (Crawled : 21:00) - prnewswire.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -0.95%
H: 2.74%
C: -4.66%
nasdaq grant therapeutics
CAR T-Cell Therapy Market to Register Stunning Growth During the Study Period (2019-2032) | DelveInsight
Published: 2024-01-23 (Crawled : 22:00) - prnewswire.com
ACLX | $52.0 0.68% 0.67% 430K
|
|
| O: 1.59%
H: 1.14%
C: -1.42%
LLY | News | $731.33 0.69% 0.0% 2.3M
|
Health Technology
|
| O: 0.61%
H: 1.52%
C: 0.03%
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: 1.57%
H: 4.94%
C: 1.54%
INCY | $51.92 -0.82% -0.83% 1.8M
|
Health Technology
|
| O: 0.29%
H: 0.15%
C: -1.95%
BEAM | $24.13 0.96% 0.95% 2.1M
|
Health Technology
|
| O: 1.88%
H: 0.88%
C: -2.79%
t-cell therapy growth study market
Manufacturing Approach in Cell Therapy as a Strategic Advantage
Published: 2024-01-17 (Crawled : 00:00) - poseida.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -1.06%
H: 5.71%
C: 1.79%
advantage cell therapy
Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting
Published: 2023-12-10 (Crawled : 20:20) - prnewswire.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
| Email alert
Add to watchlist
positive meeting car-t trial therapeutics results
Time for a Renaissance in Gene Editing and Gene Therapy
Published: 2023-11-15 (Crawled : 22:00) - poseida.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -0.45%
H: 0.91%
C: -2.27%
therapy
Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023
Published: 2023-11-09 (Crawled : 21:00) - prnewswire.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -2.73%
H: 4.44%
C: 2.34%
therapeutics financial results
Poseida Therapeutics to Present at Two Upcoming Investor Conferences - November 7, 2023
Published: 2023-11-07 (Crawled : 14:00) - biospace.com/
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -0.83%
H: 6.28%
C: 2.09%
therapeutics
Poseida Therapeutics to Present at the 65th ASH Annual Meeting and Exposition
Published: 2023-11-02 (Crawled : 13:00) - prnewswire.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: 1.45%
H: 4.29%
C: 3.81%
meeting therapeutics
Manufacturing Innovation for Allogeneic Cell Therapy: A Strategic Imperative
Published: 2023-10-26 (Crawled : 18:00) - poseida.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: 1.43%
H: 1.41%
C: -6.57%
innovation cell
It’s Time for a Change
Published: 2023-10-09 (Crawled : 22:00) - poseida.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -0.44%
H: 6.7%
C: 0.89%
change
Poseida Therapeutics Announces Leadership Transition
Published: 2023-10-09 (Crawled : 21:00) - prnewswire.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -0.44%
H: 6.7%
C: 0.89%
therapeutics
What If We’re Right?
Published: 2023-09-06 (Crawled : 19:00) - poseida.com
PSTX | $2.16 6.93% 6.48% 550K
|
Health Technology
|
| O: -0.48%
H: 2.91%
C: 2.43%
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.